TY - JOUR
T1 - A Clinical-Genetic Score for Predicting Weight Loss after Bariatric Surgery :
T2 - The OBEGEN Study
AU - Ciudin, Andreea
AU - Fidilio, Enzamaría
AU - Gutiérrez-Carrasquilla, Liliana
AU - Caixàs i Pedragós, Assumpta
AU - Vilarrasa, Núria
AU - Pellitero, Silvia
AU - Simó-Servat, Andreu
AU - Vilallonga, Ramon
AU - García Ruiz de Gordejuela, Amador
AU - de la Fuente, Maricruz
AU - Luna, Alexis
AU - Sánchez, Enric
AU - Rigla Cros, Mercedes
AU - Hernández, Cristina
AU - Salas, Eduardo
AU - Simó Canonge, Rafael
AU - Lecube, Albert
PY - 2021
Y1 - 2021
N2 - Around 30% of the patients that undergo bariatric surgery (BS) do not reach an appropriate weight loss. The OBEGEN study aimed to assess the added value of genetic testing to clinical variables in predicting weight loss after BS. A multicenter, retrospective, longitudinal, and observational study including 416 patients who underwent BS was conducted (Clinical.Trials.gov- NCT02405949). 50 single nucleotide polymorphisms (SNPs) from 39 genes were examined. Receiver Operating Characteristic (ROC) curve analysis were used to calculate sensitivity and specificity. Satisfactory response to BS was defined as at nadir excess weight loss >50%. A good predictive model of response [area under ROC of 0.845 (95% CI 0.805-0.880), p < 0.001; sensitivity 90.1%, specificity 65.5%] was obtained by combining three clinical variables (age, type of surgery, presence diabetes) and nine SNPs located in ADIPOQ, MC4R, IL6, PPARG, INSIG2, CNR1, ELOVL6, PLIN1 and BDNF genes. This predictive model showed a significant higher area under ROC than the clinical score (p = 0.0186). The OBEGEN study shows the key role of combining clinical variables with genetic testing to increase the predictability of the weight loss response after BS. This finding will permit us to implement a personalized medicine which will be associated with a more cost-effective clinical practice.
AB - Around 30% of the patients that undergo bariatric surgery (BS) do not reach an appropriate weight loss. The OBEGEN study aimed to assess the added value of genetic testing to clinical variables in predicting weight loss after BS. A multicenter, retrospective, longitudinal, and observational study including 416 patients who underwent BS was conducted (Clinical.Trials.gov- NCT02405949). 50 single nucleotide polymorphisms (SNPs) from 39 genes were examined. Receiver Operating Characteristic (ROC) curve analysis were used to calculate sensitivity and specificity. Satisfactory response to BS was defined as at nadir excess weight loss >50%. A good predictive model of response [area under ROC of 0.845 (95% CI 0.805-0.880), p < 0.001; sensitivity 90.1%, specificity 65.5%] was obtained by combining three clinical variables (age, type of surgery, presence diabetes) and nine SNPs located in ADIPOQ, MC4R, IL6, PPARG, INSIG2, CNR1, ELOVL6, PLIN1 and BDNF genes. This predictive model showed a significant higher area under ROC than the clinical score (p = 0.0186). The OBEGEN study shows the key role of combining clinical variables with genetic testing to increase the predictability of the weight loss response after BS. This finding will permit us to implement a personalized medicine which will be associated with a more cost-effective clinical practice.
KW - Bariatric surgery
KW - Genetics
KW - Obesity
KW - Polygenic risk
KW - Weight loss
U2 - 10.3390/jpm11101040
DO - 10.3390/jpm11101040
M3 - Article
C2 - 34683180
SN - 2075-4426
VL - 11
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
ER -
